• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies.

作者信息

Yang Yang, Du Lanying

机构信息

Roy J. Carver Department of Biochemistry, Biophysics and Molecular Biology, Iowa State University, Ames, IA, USA.

Howard Hughes Medical Institute, Yale University, New Haven, CT, USA.

出版信息

Signal Transduct Target Ther. 2021 Feb 26;6(1):95. doi: 10.1038/s41392-021-00523-5.

DOI:10.1038/s41392-021-00523-5
PMID:33637679
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7908000/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3055/7910443/c80360c7494e/41392_2021_523_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3055/7910443/c80360c7494e/41392_2021_523_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3055/7910443/c80360c7494e/41392_2021_523_Fig1_HTML.jpg

相似文献

1
SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies.严重急性呼吸综合征冠状病毒2刺突蛋白：引发持久中和抗体的关键靶点。
Signal Transduct Target Ther. 2021 Feb 26;6(1):95. doi: 10.1038/s41392-021-00523-5.
2
Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.SARS-COV-2 刺突糖蛋白的优化假型条件。
J Virol. 2020 Oct 14;94(21). doi: 10.1128/JVI.01062-20.
3
Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection.在小鼠模型中观察到针对贝塔冠状病毒刺突蛋白的原始抗原性感染反应，但在儿童感染 SARS-CoV-2 后并不明显。
PLoS One. 2021 Aug 27;16(8):e0256482. doi: 10.1371/journal.pone.0256482. eCollection 2021.
4
Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.利用具有 SARS-CoV-2 刺突蛋白的水疱性口炎病毒评估 SARS-CoV-2 中和抗体。
Virol J. 2021 Jan 12;18(1):16. doi: 10.1186/s12985-021-01490-7.
5
Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil.基因组证据表明巴西出现涉及 Spike 蛋白 E484K 突变的 SARS-CoV-2 再感染。
Emerg Infect Dis. 2021 May;27(5):1522-1524. doi: 10.3201/eid2705.210191. Epub 2021 Feb 19.
6
SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study.SARS-CoV-2 特异性中和抗体反应在 COVID-19 大流行第一波后挪威医护人员中的前瞻性队列研究。
J Infect Dis. 2021 Feb 24;223(4):589-599. doi: 10.1093/infdis/jiaa737.
7
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.针对 SARS-CoV-2 刺突蛋白多个表位的强效中和抗体。
Nature. 2020 Aug;584(7821):450-456. doi: 10.1038/s41586-020-2571-7. Epub 2020 Jul 22.
8
Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies.一种用于检测新型冠状病毒刺突蛋白特异性抗体的间接酶联免疫吸附测定法的开发与特性分析
J Immunol Methods. 2021 Mar;490:112958. doi: 10.1016/j.jim.2021.112958. Epub 2021 Jan 4.
9
Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library.针对 SARS-CoV-2 受体结合域的中和抗体，该抗体源自一个原始的人源抗体文库。
Protein Sci. 2021 Apr;30(4):716-727. doi: 10.1002/pro.4044. Epub 2021 Feb 24.
10
Characterization of SARS-CoV-2 worldwide transmission based on evolutionary dynamics and specific viral mutations in the spike protein.基于刺突蛋白的进化动态和特定病毒突变对 SARS-CoV-2 全球传播的特征分析。
Infect Dis Poverty. 2021 Aug 21;10(1):112. doi: 10.1186/s40249-021-00895-4.

引用本文的文献

1
Mapping of human monoclonal antibody responses to XBB.1.5 COVID-19 monovalent vaccines: a B cell analysis.人类单克隆抗体对XBB.1.5新冠单价疫苗反应的图谱绘制：一项B细胞分析
Lancet Microbe. 2025 May 30:101103. doi: 10.1016/j.lanmic.2025.101103.
2
Long-Term Dynamics of SARS-CoV-2 Variant-Specific Neutralizing Antibodies Following mRNA Vaccination and Infection.mRNA疫苗接种和感染后SARS-CoV-2变体特异性中和抗体的长期动态变化
Viruses. 2025 May 6;17(5):675. doi: 10.3390/v17050675.
3
Nanobodies: From Discovery to AI-Driven Design.纳米抗体：从发现到人工智能驱动的设计

本文引用的文献

1
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.针对 SARS-CoV-2 感染的强大中和抗体可长期存在。
Science. 2020 Dec 4;370(6521):1227-1230. doi: 10.1126/science.abd7728. Epub 2020 Oct 28.
2
Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.COVID-19 患者中针对 SARS-CoV-2 刺突蛋白受体结合域的人抗体反应的持久性和衰减。
Sci Immunol. 2020 Oct 8;5(52). doi: 10.1126/sciimmunol.abe0367.
3
Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization.
Biology (Basel). 2025 May 14;14(5):547. doi: 10.3390/biology14050547.
4
Geographical Differences in SARS-CoV-2 Antibody Response Dynamics and Neutralisation Profiles to Mild COVID-19: Lessons from a UK-Uganda Comparison.SARS-CoV-2抗体反应动力学及对轻度新冠肺炎中和谱的地理差异：英乌比较的经验教训
Vaccines (Basel). 2025 Mar 21;13(4):336. doi: 10.3390/vaccines13040336.
5
SARS-CoV-2 humoral immune responses in convalescent individuals over 12 months reveal severity-dependent antibody dynamics.康复超过12个月的个体中SARS-CoV-2的体液免疫反应揭示了严重程度依赖性抗体动态变化。
Commun Med (Lond). 2025 May 2;5(1):149. doi: 10.1038/s43856-025-00828-4.
6
Dual-Locking the SARS-CoV-2 Spike Trimer: An Amphipathic Molecular "Bolt" Stabilizes Conserved Druggable Interfaces for Coronavirus Inhibition.双重锁定严重急性呼吸综合征冠状病毒2刺突三聚体：一种两亲性分子“螺栓”稳定保守的可药物靶向界面以抑制冠状病毒
Adv Sci (Weinh). 2025 Jul;12(27):e2417534. doi: 10.1002/advs.202417534. Epub 2025 Apr 26.
7
Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.哥伦比亚对新冠病毒疫苗接种特异性抗体反应的纵向随访
J Med Virol. 2025 Jan;97(1):e70133. doi: 10.1002/jmv.70133.
8
mRNA vaccines with RBD mutations have broad-spectrum activity against SARS-CoV-2 variants in mice.携带受体结合域（RBD）突变的信使核糖核酸（mRNA）疫苗对小鼠体内的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体具有广谱活性。
NPJ Vaccines. 2025 Jan 13;10(1):7. doi: 10.1038/s41541-025-01066-4.
9
Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines.针对mRNA-1273和NVX-CoV2373新冠疫苗的多克隆抗体反应的结构血清学
bioRxiv. 2024 Dec 12:2024.12.11.628030. doi: 10.1101/2024.12.11.628030.
10
Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study.不同COVID-19严重程度等级的肯尼亚SARS-CoV-2感染者中自然诱导的抗SARS-CoV-2抗体结合水平、中和抗体水平及效力的动力学：一项观察性研究
Wellcome Open Res. 2024 Dec 2;8:350. doi: 10.12688/wellcomeopenres.19414.2. eCollection 2023.
恢复期血浆抗 SARS-CoV-2 刺突蛋白胞外域和受体结合域 IgG 与病毒中和相关。
J Clin Invest. 2020 Dec 1;130(12):6728-6738. doi: 10.1172/JCI141206.
4
Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2.低致病性人类冠状病毒特异性抗体对严重急性呼吸综合征冠状病毒2的影响。
Trends Immunol. 2020 Oct;41(10):853-854. doi: 10.1016/j.it.2020.08.003. Epub 2020 Aug 11.
5
Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses.针对新兴致病性人类冠状病毒的亚单位疫苗
Front Microbiol. 2020 Feb 28;11:298. doi: 10.3389/fmicb.2020.00298. eCollection 2020.